REVOLUTION Medicines, Inc. Expands Executive Leadership Team

– Appoints Proven Clinical Development and Team-Building Leaders –

San Francisco/Redwood City, Calif., March 5, 2015 – REVOLUTION Medicines, Inc., a company focused on the discovery and development of innovative drugs derived from natural compounds, today announced the appointment of two senior executives to its leadership team to expand its capabilities in clinical development and talent management. Carole A. Sable, M.D., an accomplished clinical scientist and R&D leader with a track record of successful drug development and registration in infectious diseases and other therapeutic areas, has joined the company as chief medical officer. In addition, Luan M. Wilfong, an expert in organizational development who has led human resources teams in the biotechnology and technology sectors, has joined as vice president, human resources.

REVOLUTION Medicines' first drug candidates are innovative small molecules that exploit and improve upon the properties of amphotericin B, a powerful, broad-spectrum antifungal compound found in nature that has avoided generating significant drug resistance in 50 years of clinical use. Dr. Sable will lead the company's clinical development strategy and execution, with an initial focus on the antifungal program. She joins REVOLUTION Medicines after serving as chief medical officer of Scynexis, a company that develops new anti-infective drugs. Previously, she held senior leadership roles in clinical development at Merck and Novexel SA, and was responsible for the development of caspofungin (Cancidas), the first antifungal drug in the echinocandin class. She has also successfully developed drugs in other therapeutic areas, including Belsomra, the first orexin receptor antagonist for the treatment of insomnia.

REVOLUTION Medicines is rapidly expanding its R&D organization to meet ambitious research and product development goals. To support this growth, as vice president, human resources Ms. Wilfong will be responsible for driving recruitment and retention of talent in all domains. She joins the company most recently from Audience, a leader in advanced voice and audio processing for mobile devices, where she was vice president of human resources. Previously, she held additional leadership positions in technology and biotechnology companies, including Gilead Sciences.

"Our mission is to bring to patients the best possible therapies by making use of evolution's important lessons in biology and chemistry and bringing to bear the full power of our advanced chemistry synthesis capabilities," said Mark A. Goldsmith, M.D., Ph.D., president and chief executive officer of REVOLUTION Medicines. "With the key hires announced today, we take another important step in building the outstanding team that will be able to fulfill these ambitions. With her impressive record of accomplishment in the clinical sciences, Carole's appointment both validates and enhances the value of our pipeline. Likewise, Luan's deep experience in recruiting and organizing talented professionals will accelerate the maturation of our organization."

About REVOLUTION Medicines

The mission of REVOLUTION Medicines is redesigning evolution's products to treat serious diseases. The company discovers and develops new drugs by reconfiguring natural substances that are inherently rich with biological function as a result of natural selection. The company's first drug candidates are innovative small molecules that exploit and improve upon the properties of amphotericin B, a powerful, broad-spectrum antifungal compound found in nature that has avoided generating significant drug resistance in 50 years of clinical use. Headquartered in Redwood City, Calif. at the intersection of Silicon Valley and the birthplace of biotechnology, REVOLUTION Medicines is a private company financed by top-tier investor Third Rock Ventures. For more information, please visit www.revolutionmedicines.com.

Suggested Articles

Disarm Therapeutics signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant, as its full-time CEO.

Pact Pharma launched a phase 1 trial of a technology designed to attack solid tumors with CAR-T cells tailored to individual patients.

Intec's candidate uses a drug delivery system designed to improve on Merck’s Sinemet but was unable to beat the product in a late-phase test.